Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy.
Bordron A, Bagacean C, Mohr A, Tempescul A, Bendaoud B, Deshayes S, Dalbies F, Buors C, Saad H, Berthou C, Pers JO, Renaudineau Y. Bordron A, et al. Among authors: berthou c. Oncotarget. 2018 Aug 3;9(60):31590-31605. doi: 10.18632/oncotarget.25657. eCollection 2018 Aug 3. Oncotarget. 2018. PMID: 30167081 Free PMC article.
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.
Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, Bendaoud B, Saad H, Zdrenghea M, Berthou C, Paintaud G, Renaudineau Y. Bagacean C, et al. Among authors: berthou c. J Immunother Cancer. 2019 Jan 29;7(1):22. doi: 10.1186/s40425-019-0509-0. J Immunother Cancer. 2019. PMID: 30696487 Free PMC article.
The regulatory capacity of B cells directs the aggressiveness of CLL.
Mohr A, Cumin M, Bagacean C, Pochard P, Le Dantec C, Hillion S, Renaudineau Y, Berthou C, Tempescul A, Saad H, Pers JO, Bordron A, Jamin C. Mohr A, et al. Among authors: berthou c. Oncoimmunology. 2018 Dec 12;8(3):1554968. doi: 10.1080/2162402X.2018.1554968. eCollection 2019. Oncoimmunology. 2018. PMID: 30723588 Free PMC article.
STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia.
Debant M, Burgos M, Hemon P, Buscaglia P, Fali T, Melayah S, Le Goux N, Vandier C, Potier-Cartereau M, Pers JO, Tempescul A, Berthou C, Bagacean C, Mignen O, Renaudineau Y. Debant M, et al. Among authors: berthou c. J Immunother Cancer. 2019 Apr 23;7(1):111. doi: 10.1186/s40425-019-0591-3. J Immunother Cancer. 2019. PMID: 31014395 Free PMC article.
Complement System: a Neglected Pathway in Immunotherapy.
Bordron A, Bagacean C, Tempescul A, Berthou C, Bettacchioli E, Hillion S, Renaudineau Y. Bordron A, et al. Among authors: berthou c. Clin Rev Allergy Immunol. 2020 Apr;58(2):155-171. doi: 10.1007/s12016-019-08741-0. Clin Rev Allergy Immunol. 2020. PMID: 31144209 Review.
CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes.
Garaud S, Taher TE, Debant M, Burgos M, Melayah S, Berthou C, Parikh K, Pers JO, Luque-Paz D, Chiocchia G, Peppelenbosch M, Isenberg DA, Youinou P, Mignen O, Renaudineau Y, Mageed RA. Garaud S, et al. Among authors: berthou c. Cell Mol Immunol. 2018 Feb;15(2):158-170. doi: 10.1038/cmi.2016.42. Epub 2016 Aug 8. Cell Mol Immunol. 2018. PMID: 27499044 Free PMC article.
275 results